Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback